GlassScriptPhysician profile
Sawsan Rashdan
NPI 1316173610
$31,568.08
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,951 · 2020: $5,450 · 2021: $14.50 · 2022: $8,063 · 2023: $2,361 · 2024: $8,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Honoraria: $750 · Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,181.50 |
| Honoraria | $750.00 |
| Food and Beverage | $158.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,912.69 | 2019-2024 | Tagrisso, Imfinzi |
| Daiichi Sankyo INC. | $3,082.50 | 2024 | |
| Amgen INC. | $2,000.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,575.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,575.00 | 2023 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $785.64 | 2023 | Firdapse |
| Eli Lilly and Company | $105.32 | 2024 | |
| Merck Sharp & Dohme LLC | $17.43 | 2024 | Keytruda |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sawsan Rashdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.